{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:43:41Z","timestamp":1770680621942,"version":"3.49.0"},"reference-count":48,"publisher":"Akademiai Kiado Zrt.","issue":"2","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University of Maryland Drug Treatment Center"},{"name":"Program for Research Initiated by Medical Students at the University of Maryland School of Medicine"},{"name":"Center for Psychedelic Drug Research and Education in the College of Social Work at Ohio State University"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["JPS"],"published-print":{"date-parts":[[2022,9,23]]},"abstract":"Abstract<\/jats:title>\n \n Background and aims<\/jats:title>\n There is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst a cohort of Black individuals diagnosed with OUD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using a convenience sampling approach, patients were recruited from an urban methadone treatment program and paid five dollars to complete an anonymous phone-based survey.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Twenty-eight patients participated (mean age 53.8; N<\/jats:italic> = 28; 35.7% female). Most (N<\/jats:italic> = 23; 82.1%) had \u201cheard of\u201d psilocybin mushrooms before taking the survey, but only five (N<\/jats:italic> = 5; 17.8%) had ever used them. More than 80% perceived a risk or were \u201cunsure\u201d of the risk for sixteen of the seventeen items queried about psilocybin. Approximately half (N<\/jats:italic> = 15; 53.6%) were willing to try therapy incorporating psilocybin and half (N<\/jats:italic> = 14; 50%) said they would be more likely to try if it were FDA approved for OUD. Most (N<\/jats:italic> = 18; 64.3%) preferred to stay on methadone treatment alone, 32.1% (N<\/jats:italic> = 9) wanted to try treatment with both psilocybin and methadone, and only one participant opted for psilocybin treatment without methadone.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Many Black individuals with Opioid Use Disorder perceive psilocybin as dangerous and may be hesitant to try psilocybin treatment. Culturally informed treatment models, educational interventions and community outreach programs should be developed to increase racial\/ethnic minority representation in psilocybin research and treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1556\/2054.2022.00214","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T14:56:39Z","timestamp":1659711399000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":6,"title":["Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder"],"prefix":"10.1556","volume":"6","author":[{"given":"John M.","family":"Clifton","sequence":"first","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle M.","family":"Belcher","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron D.","family":"Greenblatt","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Welsh","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas O.","family":"Cole","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan K.","family":"Davis","sequence":"additional","affiliation":[{"name":"Center for Psychedelic Drug Research and Education, College of Social Work, The Ohio State University, 1947 College Rd, Columbus, OH 43210, USA"},{"name":"Department of Psychiatry, College of Medicine, The Ohio State University, 370 W. 9th Avenue, Columbus, OH 43210, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"issue":"6","key":"B1","series-title":"The Journal of Nervous and Mental Disease","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/NMD.0000000000000828","article-title":"A survey of American psychiatrists' attitudes toward classic hallucinogens","volume":"206","author":"Barnett, B. S.","year":"2018","unstructured":"Barnett, B. S.\n , \n Siu, W. O.\n , & \n Pope, H. G., Jr.\n \n (2018). A survey of American psychiatrists' attitudes toward classic hallucinogens. \n The Journal of Nervous and Mental Disease\n , 206(6), 476\u2013480. https:\/\/doi.org\/10.1097\/NMD.0000000000000828.10.1097\/NMD.0000000000000828"},{"issue":"3","key":"B2","series-title":"Journal of Psychopharmacology","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz, M. P.","year":"2015","unstructured":"Bogenschutz, M. P.\n , \n Forcehimes, A. A.\n , \n Pommy, J. A.\n , \n Wilcox, C. E.\n , \n Barbosa, P. C. R.\n , & \n Strassman, R. J.\n \n (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. \n Journal of Psychopharmacology\n , 29(3), 289\u2013299. https:\/\/doi.org\/10.1177\/0269881114565144.10.1177\/0269881114565144"},{"key":"B3","series-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz, M. P.","year":"2016","unstructured":"Bogenschutz, M. P.\n , & \n Johnson, M. W.\n \n (2016). Classic hallucinogens in the treatment of addictions. \n Progress in Neuro-Psychopharmacology & Biological Psychiatry\n , 64, 250\u2013258. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.03.002.10.1016\/j.pnpbp.2015.03.002"},{"key":"B4","series-title":"Irish Journal of Medical Science","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","article-title":"Psychedelic perceptions: Mental health service user attitudes to psilocybin therapy","volume":"191","author":"Corrigan, K.","year":"2021","unstructured":"Corrigan, K.\n , \n Haran, M.\n , \n McCandliss, C.\n , \n McManus, R.\n , \n Cleary, S.\n , \n Trant, R.\n , et\u00a0al.\n (2021). Psychedelic perceptions: Mental health service user attitudes to psilocybin therapy. \n Irish Journal of Medical Science\n , 191, 1385\u20131397. https:\/\/doi.org\/10.1007\/s11845-021-02668-2.10.1007\/s11845-021-02668-2"},{"key":"B5","series-title":"Journal of Psychoactive Drugs","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2021.1971343","article-title":"Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States","author":"Davis, A. K.","year":"2021","unstructured":"Davis, A. K.\n , \n Agin-Liebes, G.\n , \n Espa\u00f1a, M.\n , \n Pilecki, B.\n , & \n Luoma, J.\n \n (2021). Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. \n Journal of Psychoactive Drugs\n , 1\u201310. https:\/\/doi.org\/10.1080\/02791072.2021.1971343.10.1080\/02791072.2021.1971343"},{"issue":"7","key":"B6","series-title":"Journal of Psychopharmacology","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MEO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","author":"Davis, A. K.","year":"2018","unstructured":"Davis, A. K.\n , \n Barsuglia, J. P.\n , \n Lancelotta, R.\n , \n Grant, R. M.\n , & \n Renn, E.\n \n (2018). The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MEO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. \n Journal of Psychopharmacology\n , 32(7), 779\u2013792. https:\/\/doi.org\/10.1177\/0269881118769063.10.1177\/0269881118769063"},{"key":"B7","series-title":"Chronic Stress","doi-asserted-by":"publisher","DOI":"10.1177\/24705470211035607","article-title":"Increases in psychological flexibility mediate the relationship between acute psychedelic drug effects and decreases in racial trauma symptoms among people of color","volume":"5","author":"Davis, A. K.","year":"2021","unstructured":"Davis, A. K.\n , \n Xin, Y.\n , \n Sepeda, N. D.\n , \n Garcia-Romeu, A.\n , & \n Williams, M. T.\n \n (2021). Increases in psychological flexibility mediate the relationship between acute psychedelic drug effects and decreases in racial trauma symptoms among people of color. \n Chronic Stress\n , 5, 24705470211035607.10.1177\/24705470211035607"},{"issue":"2","key":"B8","series-title":"Pharmacology Biochemistry and Behavior","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/0091-3057(86)90370-9","article-title":"Opioid-hallucinogen interactions","volume":"24","author":"Domino, E. F.","year":"1986","unstructured":"Domino, E. F.\n \n (1986). Opioid-hallucinogen interactions. \n Pharmacology Biochemistry and Behavior\n , 24(2), 401\u2013405. https:\/\/doi.org\/10.1016\/0091-3057(86)90370-9.10.1016\/0091-3057(86)90370-9"},{"issue":"9","key":"B9","series-title":"Expert Review of Clinical Pharmacology","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews","volume":"11","author":"Dos Santos, R. G.","year":"2018","unstructured":"Dos Santos, R. G.\n , \n Bouso, J. C.\n , \n Alc\u00e1zar-C\u00f3rcoles, M. \u00c1.\n , & \n Hallak, J.\u00a0E. C.\n \n (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. \n Expert Review of Clinical Pharmacology\n , 11(9), 889\u2013902.10.1080\/17512433.2018.1511424"},{"key":"B10","series-title":"Subchapter 1: Control and enforcement. Title 21 United States code (USC) controlled substances Act","author":"Drug Enforcement Administration","year":"1970","unstructured":"Drug Enforcement Administration\n (1970). \n Subchapter 1: Control and enforcement. Title 21 United States code (USC) controlled substances Act\n . U.S. Department of Justice. https:\/\/www.deadiversion.usdoj.gov\/21cfr\/21usc\/812.htm."},{"key":"B11","series-title":"Journal of Substance Abuse Treatment","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2019.08.002","article-title":"Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder","volume":"106","author":"Evans, E. A.","year":"2019","unstructured":"Evans, E. A.\n , \n Yoo, C.\n , \n Huang, D.\n , \n Saxon, A. J.\n , & \n Hser, Y.-I.\n \n (2019). Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. \n Journal of Substance Abuse Treatment\n , 106, 19\u201328. https:\/\/doi.org\/10.1016\/j.jsat.2019.08.002.10.1016\/j.jsat.2019.08.002"},{"key":"B12","series-title":"Current Opinion in Psychology","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.copsyc.2015.03.012","article-title":"Risk perceptions and health behavior","volume":"5","author":"Ferrer, R. A.","year":"2015","unstructured":"Ferrer, R. A.\n , & \n Klein, W. M. P.\n \n (2015). Risk perceptions and health behavior. \n Current Opinion in Psychology\n , 5, 85\u201389. https:\/\/doi.org\/10.1016\/j.copsyc.2015.03.012.10.1016\/j.copsyc.2015.03.012"},{"key":"B13","series-title":"Frontiers in Psychiatry","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey","volume":"10","author":"Garcia-Romeu, A.","year":"2020","unstructured":"Garcia-Romeu, A.\n , \n Davis, A. K.\n , \n Erowid, E.\n , \n Erowid, F.\n , \n Griffiths, R. R.\n , & \n Johnson, M. W.\n \n (2020). Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. \n Frontiers in Psychiatry\n , 10. https:\/\/doi.org\/10.3389\/fpsyt.2019.00955.10.3389\/fpsyt.2019.00955"},{"issue":"4","key":"B14","series-title":"Experimental and Clinical Psychopharmacology","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: A review","volume":"24","author":"Garcia-Romeu, A.","year":"2016","unstructured":"Garcia-Romeu, A.\n , \n Kersgaard, B.\n , & \n Addy, P. H.\n \n (2016). Clinical applications of hallucinogens: A review. \n Experimental and Clinical Psychopharmacology\n , 24(4), 229\u2013268. https:\/\/doi.org\/10.1037\/pha0000084.10.1037\/pha0000084"},{"issue":"1","key":"B15","series-title":"Journal of Psychedelic Studies","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1556\/2054.2019.015","article-title":"The psychedelic renaissance and the limitations of a white-dominant medical framework: A call for indigenous and ethnic minority inclusion","volume":"4","author":"George, J. R.","year":"2019","unstructured":"George, J. R.\n , \n Michaels, T. I.\n , \n Sevelius, J.\n , & \n Williams, M. T.\n \n (2019). The psychedelic renaissance and the limitations of a white-dominant medical framework: A call for indigenous and ethnic minority inclusion. \n Journal of Psychedelic Studies\n , 4(1), 4\u201315. https:\/\/doi.org\/10.1556\/2054.2019.015.10.1556\/2054.2019.015"},{"issue":"1","key":"B16","series-title":"Substance Abuse Treatment, Prevention, and Policy","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-017-0113-6","article-title":"Identifying and reducing disparities in successful addiction treatment completion: Testing the role of Medicaid Payment Acceptance","volume":"12","author":"Guerrero, E. G.","year":"2017","unstructured":"Guerrero, E. G.\n , \n Garner, B. R.\n , \n Cook, B.\n , \n Kong, Y.\n , \n Vega, W. A.\n , & \n Gelberg, L.\n \n (2017). Identifying and reducing disparities in successful addiction treatment completion: Testing the role of Medicaid Payment Acceptance. \n Substance Abuse Treatment, Prevention, and Policy\n , 12(1). https:\/\/doi.org\/10.1186\/s13011-017-0113-6.10.1186\/s13011-017-0113-6"},{"key":"B17","series-title":"Drug and Alcohol Dependence","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City","volume":"164","author":"Hansen, H.","year":"2016","unstructured":"Hansen, H.\n , \n Siegel, C.\n , \n Wanderling, J.\n , & \n DiRocco, D.\n \n (2016). Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. \n Drug and Alcohol Dependence\n , 164, 14\u201321. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.03.028.10.1016\/j.drugalcdep.2016.03.028"},{"key":"B18","series-title":"Substance Abuse Treatment, Prevention, and Policy","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-016-0085-y","article-title":"Systemic and individual factors in the buprenorphine treatment-seeking process: A qualitative study","volume":"12","author":"Hewell, V. M.","year":"2017","unstructured":"Hewell, V. M.\n , \n Vasquez, A. R.\n , & \n Rivkin, I. D.\n \n (2017). Systemic and individual factors in the buprenorphine treatment-seeking process: A qualitative study. \n Substance Abuse Treatment, Prevention, and Policy\n , 12 \n Article No. 3 \n https:\/\/doi.org\/10.1186\/s13011-016-0085-y.10.1186\/s13011-016-0085-y"},{"issue":"2","key":"B20","series-title":"Journal of Psychedelic Studies","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1556\/2054.2021.00166","article-title":"Racial\/ethnic differences in prevalence of hallucinogen use by age cohort: Findings from the 2018 national survey on drug use and health","volume":"5","author":"Jahn, Z. W.","year":"2021","unstructured":"Jahn, Z. W.\n , \n Lopez, J.\n , \n de la Salle, S.\n , \n Faber, S.\n , & \n Williams, M. T.\n \n (2021). Racial\/ethnic differences in prevalence of hallucinogen use by age cohort: Findings from the 2018 national survey on drug use and health. \n Journal of Psychedelic Studies\n , 5(2), 69\u201382. https:\/\/doi.org\/10.1556\/2054.2021.00166.10.1556\/2054.2021.00166"},{"issue":"11","key":"B21","series-title":"Journal of Psychopharmacology","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson, M. W.","year":"2014","unstructured":"Johnson, M. W.\n , \n Garcia-Romeu, A.\n , \n Cosimano, M. P.\n , & \n Griffiths, R. R.\n \n (2014). Pilot study of 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. \n Journal of Psychopharmacology\n , 28(11), 983\u2013992. https:\/\/doi.org\/10.1177\/0269881114548296.10.1177\/0269881114548296"},{"key":"B22","series-title":"Neuropharmacology","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson, M. W.","year":"2018","unstructured":"Johnson, M. W.\n , \n Griffiths, R. R.\n , \n Hendricks, P. S.\n , & \n Henningfield, J. E.\n \n (2018). The abuse potential of psilocybin according to the 8 factors of the Controlled Substances Act. \n Neuropharmacology\n , 142, 143\u2013166. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012.10.1016\/j.neuropharm.2018.05.012"},{"issue":"2","key":"B23","series-title":"Healthcare Manage Forum","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/0840470416679413","article-title":"Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions","volume":"30","author":"Knaak, S.","year":"2017","unstructured":"Knaak, S.\n , \n Mantler, E.\n , & \n Szeto, A.\n \n (2017). Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions. \n Healthcare Manage Forum\n , 30(2), 111\u2013116. https:\/\/doi.org\/10.1177\/0840470416679413.10.1177\/0840470416679413"},{"issue":"9","key":"B24","series-title":"JAMA Psychiatry: Research Letter","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty, P. A.","year":"2019","unstructured":"Lagisetty, P. A.\n , \n Ross, R.\n , \n Bohnert, A.\n , \n Clay, M.\n , & \n Maust, D. T.\n \n (2019). Buprenorphine treatment divide by race\/ethnicity and payment. \n JAMA Psychiatry: Research Letter\n , 76(9), 979\u2013980. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0876.10.1001\/jamapsychiatry.2019.0876"},{"issue":"10","key":"B25","series-title":"American Journal of Public Health","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2105\/AJPH.2021.306431","article-title":"Disparities in opioid overdose death trends by Race\/ethnicity, 2018\u20132019, from the Healing Communities Study","volume":"111","author":"Larochelle, M. R.","year":"2021","unstructured":"Larochelle, M. R.\n , \n Slavova, S.\n , \n Root, E. D.\n , \n Feaster, D. J.\n , \n Ward, P. J.\n , \n Selk, S. C.\n , et\u00a0al.\n (2021). Disparities in opioid overdose death trends by Race\/ethnicity, 2018\u20132019, from the Healing Communities Study. \n American Journal of Public Health\n , 111(10), 1851\u20131854. https:\/\/doi.org\/10.2105\/ajph.2021.306431.10.2105\/AJPH.2021.306431"},{"issue":"43","key":"B26","series-title":"US Department of Health and Human Services\/Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report","first-page":"967","article-title":"Racial\/ethnic and age group differences in opioid and synthetic opioid-involved overdose deaths among adults aged \u2265 18 years in metropolitan areas- United States, 2015\u20132017","volume":"68","author":"Lippold, K. M.","year":"2019","unstructured":"Lippold, K. M.\n , \n Jones, C. M.\n , \n Olsen, E. O.\n , & \n Giroir, B. P.\n \n (2019). Racial\/ethnic and age group differences in opioid and synthetic opioid-involved overdose deaths among adults aged \u2265 18 years in metropolitan areas- United States, 2015\u20132017. \n US Department of Health and Human Services\/Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report\n , 68(43), 967\u2013973."},{"issue":"1","key":"B27","series-title":"BMC Psychiatry","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature","volume":"18","author":"Michaels, T. I.","year":"2018","unstructured":"Michaels, T. I.\n , \n Purdon, J.\n , \n Collins, A.\n , & \n Williams, M. T.\n \n (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. \n BMC Psychiatry\n , 18(1). https:\/\/doi.org\/10.1186\/s12888-018-1824-6.10.1186\/s12888-018-1824-6"},{"issue":"2","key":"B28","series-title":"Journal of Psychopharmacology","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/0269881109106915","article-title":"Harms associated with psychoactive substances: Findings of the UK national drug survey","volume":"24","author":"Morgan, C. J. A.","year":"2009","unstructured":"Morgan, C. J. A.\n , \n Muetzelfeldt, L.\n , \n Muetzelfeldt, M.\n , \n Nutt, D. J.\n , & \n Curran, H. V.\n \n (2009). Harms associated with psychoactive substances: Findings of the UK national drug survey. \n Journal of Psychopharmacology\n , 24(2), 147\u2013153. https:\/\/doi.org\/10.1177\/0269881109106915.10.1177\/0269881109106915"},{"issue":"1","key":"B29","series-title":"Journal of Psychedelic Studies","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1556\/2054.2019.018","article-title":"Making psychedelics into medicines: The politics and paradoxes of medicalization","volume":"4","author":"Noorani, T.","year":"2019","unstructured":"Noorani, T.\n \n (2019). Making psychedelics into medicines: The politics and paradoxes of medicalization. \n Journal of Psychedelic Studies\n , 4(1), 34\u201339. https:\/\/doi.org\/10.1556\/2054.2019.018.10.1556\/2054.2019.018"},{"issue":"9752","key":"B30","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: A multicriteria decision analysis","volume":"376","author":"Nutt, D. J.","year":"2010","unstructured":"Nutt, D. J.\n , \n King, L. A.\n , & \n Phillips, L. D.\n \n (2010). Drug harms in the UK: A multicriteria decision analysis. \n Lancet\n , 376(9752), 1558\u20131565. https:\/\/doi.org\/10.1016\/S0140-6736(10)61462-6.10.1016\/S0140-6736(10)61462-6"},{"issue":"9566","key":"B31","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","article-title":"Development of a rational scale to assess the harm of drugs of potential misuse","volume":"369","author":"Nutt, D.","year":"2007","unstructured":"Nutt, D.\n , \n King, L. A.\n , \n Saulsbury, W.\n , & \n Blakemore, C.\n \n (2007). Development of a rational scale to assess the harm of drugs of potential misuse. \n Lancet\n , 369(9566), 1047\u20131053. https:\/\/doi.org\/10.1016\/S0140-6736(07)60464-4.10.1016\/S0140-6736(07)60464-4"},{"issue":"3","key":"B32","series-title":"Journal of Psychedelic Psychiatry","first-page":"20","article-title":"Newspaper coverage of psilocybin: Sentiment and frequency (1989-2020)","volume":"3","author":"Oliver, D.","year":"2021","unstructured":"Oliver, D.\n \n (2021). Newspaper coverage of psilocybin: Sentiment and frequency (1989-2020). \n Journal of Psychedelic Psychiatry\n , 3(3), 20\u201328."},{"key":"B33","series-title":"The American Journal on Addictions","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/ajad.12803","article-title":"Trends in DMT and other tryptamine use among young adults in the United States","volume":"27","author":"Palamar, J. J.","year":"2018","unstructured":"Palamar, J. J.\n , & \n Le, A.\n \n (2018). Trends in DMT and other tryptamine use among young adults in the United States. \n The American Journal on Addictions\n , 27, 578\u2013585. https:\/\/doi.org\/10.1111\/ajad.12803.10.1111\/ajad.12803"},{"issue":"5","key":"B34","series-title":"Journal of Psychopharmacology","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"Pisano, V. D.","year":"2017","unstructured":"Pisano, V. D.\n , \n Putnam, N. P.\n , \n Kramer, H. M.\n , \n Franciotti, K. J.\n , \n Halpern, J. H.\n , & \n Holden, S. C.\n \n (2017). The association of psychedelic use and opioid use disorders among illicit users in the United States. \n Journal of Psychopharmacology\n , 31(5), 606\u2013613. https:\/\/doi.org\/10.1177\/0269881117691453.10.1177\/0269881117691453"},{"key":"B35","series-title":"International Journal of Drug Policy","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103429","article-title":"Enhancing equity-oriented care in psychedelic medicine: Utilizing the equip framework","volume":"98","author":"Rea, K.","year":"2021","unstructured":"Rea, K.\n , & \n Wallace, B.\n \n (2021). Enhancing equity-oriented care in psychedelic medicine: Utilizing the equip framework. \n International Journal of Drug Policy\n , 98, 103429. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103429.10.1016\/j.drugpo.2021.103429"},{"issue":"7","key":"B36","series-title":"Substance Use & Misuse","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1080\/10826084.2017.1392985","article-title":"Perceived risk associated with MDMA (Ecstasy\/Molly) use among African Americans: What prevention and treatment providers should know","volume":"53","author":"Rigg, K. K.","year":"2018","unstructured":"Rigg, K. K.\n , & \n Lawenetal, M.\n \n (2018). Perceived risk associated with MDMA (Ecstasy\/Molly) use among African Americans: What prevention and treatment providers should know. \n Substance Use & Misuse\n , 53(7), 1076\u20131083. https:\/\/doi.org\/10.1080\/10826084.2017.1392985.10.1080\/10826084.2017.1392985"},{"key":"B37","series-title":"Arch Gen Psychiatry","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict","volume":"28","author":"Savage, C.","year":"1973","unstructured":"Savage, C.\n , & \n McCabe, L.\n \n (1973). Residential psychedelic (LSD) therapy for the narcotic addict. \n Arch Gen Psychiatry\n , 28, 808\u2013814. https:\/\/doi.org\/10.1001\/archpsyc.1973.01750360040005.10.1001\/archpsyc.1973.01750360040005"},{"key":"B38","series-title":"Plants of the gods: Their sacred, healing, and hallucinogenic powers","author":"Schultes, R. E.","year":"1992","unstructured":"Schultes, R. E.\n , & \n Hofmann, A.\n \n (1992). \n Plants of the gods: Their sacred, healing, and hallucinogenic powers\n . Rochester, VT: Healing Arts Press."},{"key":"B39","series-title":"BMC Health Services Research","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: An overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon, M.","year":"2017","unstructured":"Sekhon, M.\n , \n Cartwright, M.\n , & \n Francis, J. J.\n \n (2017). Acceptability of healthcare interventions: An overview of reviews and development of a theoretical framework. \n BMC Health Services Research\n , 17, 88. https:\/\/doi.org\/10.1186\/s12913-017-2031-8.10.1186\/s12913-017-2031-8"},{"key":"B49","series-title":"Clinical Pharmacology & Therapeutics","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/cpt.776","article-title":"Psychedelic drugs as therapeutics: No illusions about the challenges","volume":"103","author":"Sellers, E. M.","year":"2018","unstructured":"Sellers, E. M.\n , & \n Leiderman, D. B.\n \n (2018). Psychedelic drugs as therapeutics: No illusions about the challenges. \n Clinical Pharmacology & Therapeutics\n , 103, 561\u2013564. https:\/\/doi.org\/10.1002\/cpt.776.10.1002\/cpt.776"},{"key":"B40","series-title":"Current Psychiatry Reports","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma, A.","year":"2017","unstructured":"Sharma, A.\n , \n Kelly, S. M.\n , \n Mitchell, S. G.\n , \n Gryczynski, J.\n , \n O\u2019Grady, K. E.\n , & \n Schwartz, R. P.\n \n (2017). Update on barriers to pharmacotherapy for opioid use disorders. \n Current Psychiatry Reports\n , 19, 35. https:\/\/doi.org\/10.1007\/s11920-017-0783-9.10.1007\/s11920-017-0783-9"},{"key":"B41","series-title":"Addictive Behaviors","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.addbeh.2019.01.020","article-title":"Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore city","volume":"93","author":"Truong, C.","year":"2019","unstructured":"Truong, C.\n , \n Krawczyk, N.\n , \n Dejman, M.\n , \n Marshall-Shah, S.\n , \n Tormohlen, K.\n , \n Agus, D.\n , & \n Bass, J.\n \n (2019). Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore city. \n Addictive Behaviors\n , 93, 14\u201319.10.1016\/j.addbeh.2019.01.020"},{"issue":"3","key":"B42","series-title":"European Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin \u2013 summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161, F.","year":"2014","unstructured":"Tyl\u0161, F.\n , \n P\u00e1len\u00ed\u010dek, T.\n , & \n Hor\u00e1\u010dek, J.\n \n (2014). Psilocybin \u2013 summary of knowledge and new perspectives. \n European Neuropsychopharmacology\n , 24(3), 342\u2013356. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.12.006.10.1016\/j.euroneuro.2013.12.006"},{"key":"B50","article-title":"Population Estimates","author":"United States Census Bureau","year":"2021","unstructured":"United States Census Bureau\n . (2021). Population Estimates. Retrieved from [https:\/\/www.census.gov\/quickfacts\/fact\/table\/baltimorecitymaryland,US\/PST045221#qf-headnote-a]."},{"issue":"25","key":"B43","series-title":"JNCI Monographs","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/oxfordjournals.jncimonographs.a024192","article-title":"What does it mean to understand a risk? Evaluating risk comprehension","volume":"1999","author":"Weinstein, N. D.","year":"1999","unstructured":"Weinstein, N. D.\n \n (1999). What does it mean to understand a risk? Evaluating risk comprehension. \n JNCI Monographs\n , 1999(25), 15\u201320. https:\/\/doi.org\/10.1093\/oxfordjournals.jncimonographs.a024192.10.1093\/oxfordjournals.jncimonographs.a024192"},{"issue":"3","key":"B44","series-title":"Drugs: Education, Prevention and Policy","first-page":"215","article-title":"People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences","volume":"28","author":"Williams, M. T.","year":"2020","unstructured":"Williams, M. T.\n , \n Davis, A. K.\n , \n Xin, Y.\n , \n Sepeda, N. D.\n , \n Grigas, P. C.\n , \n Sinnott, S.\n , & \n Haeny, A. M.\n \n (2020). People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. \n Drugs: Education, Prevention and Policy\n , 28(3), 215\u2013226. https:\/\/doi.org\/10.1080\/09687637.2020.1854688."},{"issue":"1","key":"B45","series-title":"Journal of Psychedelic Studies","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/2054.2019.032","article-title":"Diversity, equity, and access in psychedelic medicine","volume":"4","author":"Williams, M. T.","year":"2019","unstructured":"Williams, M. T.\n , & \n Labate, B. C.\n \n (2019). Diversity, equity, and access in psychedelic medicine. \n Journal of Psychedelic Studies\n , 4(1), 1\u20133. https:\/\/doi.org\/10.1556\/2054.2019.032.10.1556\/2054.2019.032"},{"issue":"1","key":"B46","series-title":"Journal of Psychedelic Studies","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1556\/2054.2019.016","article-title":"Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder","volume":"4","author":"Williams, M. T.","year":"2019","unstructured":"Williams, M. T.\n , \n Reed, S.\n , & \n Aggarwal, R.\n \n (2019). Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder. \n Journal of Psychedelic Studies\n , 4(1), 40\u201350. https:\/\/doi.org\/10.1556\/2054.2019.016.10.1556\/2054.2019.016"},{"key":"B47","series-title":"GDS key finding 2019","author":"Winstock, A. R.","year":"2019","unstructured":"Winstock, A. R.\n , \n Aldreidge, A.\n , \n Maier, L. J.\n , \n Barratt, M. J.\n , \n Zhuparris, A.\n , \n Davies, E.\n , et\u00a0al.\n (2019, May 15). \n GDS key finding 2019\n . \n Issue Retrieved January 9, 2022, from \n https:\/\/issuu.com\/globaldrugsurvey\/docs\/gds2019_key_findings_report_may_16_."}],"container-title":["Journal of Psychedelic Studies"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/2054\/6\/2\/article-p80.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/2054\/6\/2\/article-p80.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/2054\/6\/2\/article-p80.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T15:59:14Z","timestamp":1663948754000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/2054\/6\/2\/article-p80.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":48,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1556\/2054.2022.00214","relation":{},"ISSN":["2559-9283"],"issn-type":[{"value":"2559-9283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}